Clinical Trial Update: Intrathecal Amniotic Fluid Stem Cells for Progressive Multiple Sclerosis [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating intrathecal amniotic fluid stem cells for progressive multiple sclerosis has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis Progressive

Drugs mentioned

• Intrathecal amniotic fluid stem cells (amniotic fluid stem cells)

Snippet

Sponsor: Wake Forest University Health Sciences | Conditions: Multiple Sclerosis, Progressive | Phase 1, Phase 2 | Status: WITHDRAWN